Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike...
Guardado en:
Autores principales: | Reka Gabriela, Pawlak Angelika, Machowiec Piotr, Maksymowicz Marcela, Piecewicz-Szczesna Halina |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Sciendo
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8d36b220768b4d5a88654c0f351f3369 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
- Monoclonal antibodies in immunodiagnosis and immunotherapy
-
The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody
por: Daniela Luz, et al.
Publicado: (2021) -
PREPARATION AND PROPERTIES OF MURINE ANTI-IDIOTYPIC MONOCLONAL ANTIBODIES RECOGNIZING PRIMARY RABBIT POLYCLONAL ANTIBODIES AGAINST MORPHINE DERIVATIVES
por: A. V. Trofimov, et al.
Publicado: (2019) -
Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <italic toggle="yes">In Vivo</italic> in a Mouse Model in a Neutralization-Dependent Manner
por: Fatima Amanat, et al.
Publicado: (2021) -
Preparation of polyclonal and monoclonal anti-idiotypic antibodies against morphine-specific immunoglobulins
por: A. V. Trofimov, et al.
Publicado: (2020)